Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT06347627 Enrolling by invitation - Healthy Clinical Trials

Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18

Start date: December 22, 2023
Phase: N/A
Study type: Interventional

This study aims to comprehensively assess confidence in and acceptance of human papillomavirus (HPV) vaccines among Japanese parents and caregivers with daughters aged 12-18 and their decision-making process.

NCT ID: NCT06343636 Enrolling by invitation - Healthy Clinical Trials

A Phase 1 Study of VG-3927 in Healthy Adults

Start date: September 27, 2023
Phase: Phase 1
Study type: Interventional

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927 in Healthy Adults

NCT ID: NCT06341634 Enrolling by invitation - Healthy Clinical Trials

Surveillance of Suicide Ideation in Adolescents (VISIA)

Start date: February 6, 2024
Study type: Observational

The goal of this observational study is to validate an AI algorithm's capability to differentiate the population with suicidal ideation from a control population using various multimodal variables, including voice analysis, facial emotions, natural language, and proteomics data. The primary research question it aims to answer is: Is it possible to identify suicidal ideation and suicide risk in adolescents early and non-intrusively using multimodal data analysis through digital instruments equipped with artificial intelligence? Participants in this study will be asked to: Complete psychometric instruments to establish a gold standard for detecting suicide risk and suicidal ideation. Provide voice recordings, facial emotion data, and linguistic content in natural and specific contexts. Participate in salivary proteomics data collection. This study compares three distinct groups: Ideation: Adolescent patients with current suicidal ideation. Clinical Population: Psychological or psychiatric patients of the same age and gender without suicidal ideation. General Population: Adolescents without known psychological or psychiatric pathology of the same age and gender, without suicidal ideation. Researchers will compare these groups to determine if the AI algorithm is effective in differentiating individuals with suicidal ideation (Group 1) from both a clinical control group (Group 2) and a general population control group (Group 3) using the collected multimodal data. The study aims to assess the algorithm's ability to identify early signs of suicide risk in these distinct participant populations.

NCT ID: NCT06332638 Enrolling by invitation - Healthy Clinical Trials

PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects

Start date: March 19, 2024
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to explore pharmacokinetics, pharmacodynamics, and safety of tegoprazan 12.5 mg in healthy subjects when orally administered as a single dose or as multiple doses twice daily.

NCT ID: NCT06325228 Enrolling by invitation - Healthy Clinical Trials

Incidence of Musculoskeletal Injuries, Sports Performance, Sports Specialization, and Quality of Life in Young Athletes

Start date: February 1, 2023
Study type: Observational

The primary aim of this observational cohort study is to assess sports specialization, sports performance, history of injuries (prevalence, types, areas, duration) and quality of life in young healthy athletes aged 8-16 from Poland. Athlete profiles will be created based on the variables (explained in detailed description) examined. Furthermore, the investigators will perform one-year injury follow-up. The main questions it aims to answer are: - Do athletes with a specific profile (lower values in athletic performance tests, low values in quality of life) evaluated at one time point, suffer injury in the future in annual observation? - Do athletes with high sports specialization will sustain injury in one-year follow-up? - Does sports specialization have a relationship with sports performance tests, and quality of life? - Does value of the specific muscle (lower limb) isometric strength will be associated with the dynamic balance scores in young healthy athletes?

NCT ID: NCT06285630 Enrolling by invitation - Healthy Clinical Trials

The Development and Health of the Intestinal Flora During the First Year of Life

Start date: February 26, 2024
Study type: Observational

In this research study (PREVENT 1), Alba Health, in collaboration with academic institutions (Uppsala University, COPSAC and University of Antwerp) is investigating the association between the developing gut microbiota (collection of microbes present in the human gut) in the first year of life and lifestyle, wellbeing and health in a Swedish population. The study is the first of its kind in a Swedish population to collect and associate microbiome composition to an extensive family history and health questionnaire, stool colour and crying type, building on learnings from previous studies performed in other countries, such as the HELMI and COPSAC studies (HELMI - Finnish Health and Early Life Microbiota cohort from the University of Helsinki in Finland; COPSAC - Copenhagen Prospective Studies on Asthma in Childhood in Denmark). The PREVENT 1 study is an observational research study led by Alba Health involving 300 families in Sweden with children between 0 and 12 months of age at the time of the study's start. After providing informed consent, the participating families will be asked to provide three stool samples from their child (the sample collection is not invasive and does not cause discomfort) and will be asked to answer questionnaires on lifestyle, well-being and family health. The participating families will not be asked to change their lifestyle beyond sample and data collection. From the collected stool samples, we will extract microbial DNA and subject this to deep metagenomic sequence analysis. The study will only analyze microbial DNA, any human related material will be discarded. The stool samples will be destroyed within one month of sequencing (maximum 3 months from collection). The data will be stored according to GDPR and Swedish law, with informed consent in Sweden and with appropriate security measures. All research will be carried out in Sweden.

NCT ID: NCT06164652 Enrolling by invitation - Healthy Clinical Trials

Evaluation of the Validity of the Ceriter Stride One in Measuring Gait and Pressure Parameters in Healthy Adults

Start date: November 30, 2023
Phase: N/A
Study type: Interventional

The Ceriter Stride One is a certified medical device that aims to provide a better, more independent and safe gait pattern for people with neurological disorders, such as Parkinson's disease. The Stride One detects the (abnormal) gait pattern via an insole with pressure sensors and generates customised audio feedback (app), e.g. to avoid or correct Freezing or Gait (Parkinson's). To gain more insight into the accuracy of the pressure and gait recordings, we want to compare them with those of the GAITRite. The GAITRite is an electronic walking carpet with an active zone 7.32m long and 0.61m wide. The carpet has pressure sensors embedded in horizontal lines. When a person steps on the carpet, these sensors capture the pressure distribution which, with the help of an algorithm, allows the collection of parameters per time unit (including speed, step time, stride time, cadence, etc.) and space (step and stride length, step and stride width, etc.). The GAITrite is considered a gold standard for capturing temporal and spatial data related to gait pattern. Our research question can be answered by having healthy subjects step over the GAITRite with the Ceriter Stride One on, and then checking the agreement between spatiotemporal factors. Thus, after IC and recording of administrative data, healthy adults will be invited for this cross-sectional validity study of a pressure-sensitive insole (Ceriter Stride One) against the validated and reliable gold standard, the GaitRite. At intake, the informed consent is gone over and signed. The inclusion and exclusion criteria are then questioned in a short interview. Inclusion criteria are pain-free and safe walking. Exclusion criteria are pregnancy and (congenital or acquired) orthopaedic, neurological and other defects that make walking without a walking aid or orthosis (or shoe adaptation) painful, difficult and/or unsafe, Ceriter insoles are placed in the test subjects' shoes, if possible in place of their own insoles, in case of orthotics on top. Via a Bluetooth transmitter, the captured signals from the pressure sensors are transmitted to and mobile phone and then via the internet to Ceriter's data portal where they are further processed and, for the purpose of this study, made available to the researchers.Subjects then step on the walking carpet with sensors (GAITRite) with these insoles in their shoes.Both systems record the pressures and analyse the gait pattern from there. Each test subject is expected to step across the walking carpet at a comfortable pace for three full lengths and 3 lengths involving acceleration. This, fitted with the insoles, so that sufficient steps are available to average out step parameters. The aim of the study is thus to find out to what extent the spatiotemporal parameters captured with the Ceriter Stride One coincide with those of the GaitRite.

NCT ID: NCT06119412 Enrolling by invitation - Healthy Clinical Trials

An Alternative Technique for Measuring Blood Pressure

Start date: October 20, 2023
Phase: N/A
Study type: Interventional

This cross design study will be conducted to evaluate the combination of palpation and auscultation techniques as an alternative technique for the measurement of blood pressure. The main questions it aims to answer are: - Is there a statistical difference between the results of systolic blood pressure measured with the old and new technique? - Is there a statistical difference between the results of systolic blood pressure measured with the old and new technique? Participants' blood pressure will be measured twice.

NCT ID: NCT06066749 Enrolling by invitation - Healthy Clinical Trials

Efficacy of Respiratory Protection Against the Effects of Wood Smoke Exposure in Young Healthy Adults (MASKON)

Start date: January 2024
Phase: N/A
Study type: Interventional

Purpose: The study is designed to investigate cardiovascular effects of young healthy human subjects exposed to wood smoke. Participants: Approximately 30 young (18-35 years old) healthy subjects to complete. Procedure (methods): After consenting to participate in the study, participants will undergo exposure to approximately 500 μg/m^3 wood smoke for 2 hours while exercising intermittently (15 min exercise followed by 15 min rest) on a stationary bike at a workload sufficient to maintain approximately 12 L/min/m^2 minute ventilation. There are a total of three separate exposure sessions. During the first two exposure sessions, participants will wear, in randomized order, a half-face elastomeric respirator fitted with particulate filters alone (hereafter referred to as "PM mask") or particulate filters and a hydrocarbon sorbent (hereafter referred to as "VOC mask"). During the third exposure session, participants will be randomly assigned to wear either a surgical mask or an N95 respirator. Venous blood samples and measurements of lung, cardiac and vascular function will be made prior to and immediately following each exposure. Induced sputum samples and nasal epithelial lining fluid will be collected approximately 24 hours post each exposure.

NCT ID: NCT06060925 Enrolling by invitation - Healthy Clinical Trials

Imaging Biomarkers for Myofascial Pain

Start date: January 1, 2023
Study type: Observational

Myofascial pain syndrome (MPS) is highly prevalent in the community. It is primarily diagnosed using patient self reports and physical examination, which lack reliability, sensitivity and specificity and does not provide insights into the abnormal biological and physiological processes in soft tissues. While a number of treatment methods are available to patients, there are currently no criteria to determine which treatments might be best for each patient's unique myofascial pain phenotype. To improve evidence-based management of myofascial pain, there is a critical need to develop quantitative measures that advance the understanding of the physiological processes in the underlying the soft tissues across the clinical continuum of MPS. The objective of this project is to develop a quantitative biomarker informed by the current understanding of underlying tissue-level mechanisms at the level of the "myofascial unit" (muscle, nerve, fascia, vasculature, lymphatics) that are likely to be involved in MPS.